Tag: AveXis

April 25, 2018

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data

AveXis (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will...
April 19, 2018

Genetics Update: Q1 in Review

With Q1 2018 officially in the books, here the Investing News Network takes a look back at what some of...
April 9, 2018

AveXis’ Share Price Soars with Acquisition Announcement

Global big pharma company Novartis started the week off on the right foot by announcing plans to acquire gene therapy...
April 9, 2018

AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion

AveXis (NASDAQ:AVXS) announced today that it has entered into an agreement and plan of merger with Novartis pursuant to which...
March 14, 2018

AveXis Enters into Licensing Agreement with Genethon

AveXis (NASDAQ:AVXS) and Genethon today announced they have entered into an exclusive, worldwide license agreement for in vivo gene therapy delivery of...
March 8, 2018

4 Gene Editing Technologies Explained

We look at four types of gene editing currently in clinical trials, as well as the pros and cons of...
February 28, 2018

AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

AveXis (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today...